Acute Lymphoblastic Leukemia: CAR-T Cell Therapy Safety and Efficacy

Clinical Trial Progress Report

• February 1, 2021

Nagoya University announced CAR-T immunotherapy trial results in acute lymphoblastic leukemia on January 25, 2021. Initial cohort (n=3, ages 10-40) demonstrates sustained remission with excellent safety after 1+ year of treatment.

CAR-T Approach

CAR-T therapy involves genetic engineering of patient immune cells to enhance anti-tumor cytotoxicity. Nagoya and Shinshu Universities developed proprietary CAR-T technology for ALL treatment.

Patient Population

Initial Cohort: 3 patients, ages 10-40 years

Treatment Indication: Treatment-refractory or post-transplant relapsed ALL

Treatment Duration: 2 months to 1+ year

Safety Results

Treatment course demonstrates excellent safety profile with no significant toxicities reported. All patients currently remain in remission.

Next Phase

Study expanding to include pediatric cohort (ages 1-15 years) to further establish CAR-T safety profile across broader age range and validate therapeutic approach for early-onset ALL.

Clinical Significance

CAR-T immunotherapy demonstrates promising safety and efficacy in ALL, supporting further clinical development for chemotherapy-refractory and post-transplant relapsed disease.

Data Source

Nagoya University Department of Pediatrics announcement

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1